In Vivo and In Vitro Pro-Fibrotic Response of Lung-Resident Mesenchymal Stem Cells from Patients with Idiopathic Pulmonary Fibrosis

dc.contributor.authorEscarrer Garau, Gabriel
dc.contributor.authorMartín Medina, Aina
dc.contributor.authorTruyols Vives, Joan
dc.contributor.authorGómez Bellvert, Cristina
dc.contributor.authorElowsson, Linda
dc.contributor.authorWestergren Thorsson, Gunilla
dc.contributor.authorMolina Molina, María
dc.contributor.authorMercader Barceló, Josep
dc.contributor.authorSala Llinàs, Ernest
dc.date.accessioned2025-12-16T11:43:51Z
dc.date.available2025-12-16T11:43:51Z
dc.date.issued2024-01-16
dc.date.updated2025-12-05T11:33:51Z
dc.description.abstractLung-resident mesenchymal stem cells (LR-MSC) are thought to participate in idiopathic pulmonary fibrosis (IPF) by differentiating into myofibroblasts. On the other hand, LR-MSC in IPF patients present senescence-related features. It is unclear how they respond to a profibrotic environment. Here, we investigated the profibrotic response of LR-MSC isolated from IPF and control (CON) patients. LR-MSC were inoculated in mice 48 h after bleomycin (BLM) instillation to analyze their contribution to lung damage. In vitro, LR-MSC were exposed to TGF beta. Mice inoculated with IPF LR-MSC exhibited worse maintenance of their body weight. The instillation of either IPF or CON LR-MSC sustained BLM-induced histological lung damage, bronchoalveolar lavage fluid cell count, and the expression of the myofibroblast marker, extracellular matrix (ECM) proteins, and proinflammatory cytokines in the lungs. In vitro, IPF LR-MSC displayed higher basal protein levels of aSMA and fibronectin than CON LR-MSC. However, the TGF beta response in the expression of TGF beta, aSMA, and ECM genes was attenuated in IPF LR-MSC. In conclusion, IPF LR-MSC have acquired myofibroblastic features, but their capacity to further respond to profibrotic stimuli seems to be attenuated. In an advanced stage of the disease, LR-MSC may participate in disease progression owing to their limited ability to repair epithelial damage.
dc.format.extent13 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2073-4409
dc.identifier.pmid38247851
dc.identifier.urihttps://hdl.handle.net/2445/224974
dc.language.isoeng
dc.publisherMDPI AG
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/cells13020160
dc.relation.ispartofCells, 2024, vol. 13, num. 2, 160
dc.relation.urihttps://doi.org/10.3390/cells13020160
dc.rightscc-by (c) Escarrer Garau, Gabriel et al., 2024
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationFibrosi pulmonar
dc.subject.classificationMalalties pulmonars obstructives cròniques
dc.subject.classificationFarmacologia respiratòria
dc.subject.otherPulmonary fibrosis
dc.subject.otherChronic obstructive pulmonary diseases
dc.subject.otherPulmonary pharmacology
dc.titleIn Vivo and In Vitro Pro-Fibrotic Response of Lung-Resident Mesenchymal Stem Cells from Patients with Idiopathic Pulmonary Fibrosis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
cells-13-00160 (1).pdf
Mida:
1.68 MB
Format:
Adobe Portable Document Format